Kaltsas A, Giannakas T, Stavropoulos M, Kratiras Z, Chrisofos M
Diseases. 2025; 13(2).
PMID: 39997060
PMC: 11854834.
DOI: 10.3390/diseases13020053.
Fu X, Liu H, Liu J, DiSanto M, Zhang X
Cells. 2022; 11(13).
PMID: 35805135
PMC: 9266107.
DOI: 10.3390/cells11132052.
Elbaz E, Amin H, Kamel A, Ibrahim S, Helmy H
Inflammopharmacology. 2020; 28(5):1407-1420.
PMID: 32785828
DOI: 10.1007/s10787-020-00743-1.
Pigat N, Reyes-Gomez E, Boutillon F, Palea S, Barry Delongchamps N, Koch E
Front Pharmacol. 2019; 10:311.
PMID: 30984003
PMC: 6450068.
DOI: 10.3389/fphar.2019.00311.
Tsikas D, Schwedhelm K, Surdacki A, Giustarini D, Rossi R, Kukoc-Modun L
J Pharm Anal. 2018; 8(1):1-9.
PMID: 29568662
PMC: 5859134.
DOI: 10.1016/j.jpha.2017.12.003.
A Variant in the Precursor of MicroRNA-146a is Responsible for Development of Erectile Dysfunction in Patients with Chronic Prostatitis via Targeting NOS1.
Ding J, Tang Y, Tang Z, Zhang X, Wang G
Med Sci Monit. 2017; 23:929-937.
PMID: 28218896
PMC: 5330210.
DOI: 10.12659/msm.898406.
Oxidative stress in prostate hyperplasia and carcinogenesis.
Udensi U, Tchounwou P
J Exp Clin Cancer Res. 2016; 35(1):139.
PMID: 27609145
PMC: 5017015.
DOI: 10.1186/s13046-016-0418-8.
Inhibitory Activities of Phenolic Compounds Isolated from Adina rubella Leaves Against 5α-Reductase Associated with Benign Prostatic Hypertrophy.
Yin J, Heo J, Hwang Y, Le T, Lee M
Molecules. 2016; 21(7).
PMID: 27399661
PMC: 6273293.
DOI: 10.3390/molecules21070887.
Inflammatory Signaling Involved in High-Fat Diet Induced Prostate Diseases.
Shankar E, Bhaskaran N, MacLennan G, Liu G, Daneshgari F, Gupta S
J Urol Res. 2015; 2(1).
PMID: 26417612
PMC: 4583131.
Nitric Oxide Synthase is Necessary for Normal Urogenital Development.
Bond C, Cakir O, McVary K, Podlasek C
Andrology (Los Angel). 2014; 2:108.
PMID: 24900949
PMC: 4041737.
DOI: 10.4172/2167-0250.1000108.
Is transforming growth factor-β signaling activated in human hypertrophied prostate treated by 5-alpha reductase inhibitor?.
Kim H, Zhao C, Choi B, Chae H, Kim D, Park J
Dis Markers. 2013; 35(6):679-85.
PMID: 24311892
PMC: 3838824.
DOI: 10.1155/2013/783287.
Update on Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia.
Elterman D, Chughtai B, Lee R, Te A, Kaplan S
Rev Urol. 2013; 14(3-4):79-86.
PMID: 23526698
PMC: 3602730.
Observational study: daily treatment with a new compound "Tradamixina" plus serenoa repens for two months improved the lower urinary tract symptoms.
Iacono F, Prezioso D, Illiano E, Ruffo A, Romeo G, Amato B
BMC Surg. 2012; 12 Suppl 1:S22.
PMID: 23173650
PMC: 3499205.
DOI: 10.1186/1471-2482-12-S1-S22.
Blood and tissue nitric oxide and malondialdehyde are prognostic indicators of localized prostate cancer.
Ozlen Dillioglugil M, Mekik H, Muezzinoglu B, Ozkan T, Demir C, Dillioglugil O
Int Urol Nephrol. 2012; 44(6):1691-6.
PMID: 22710971
DOI: 10.1007/s11255-012-0221-1.
The functional role of reactive stroma in benign prostatic hyperplasia.
Schauer I, Rowley D
Differentiation. 2011; 82(4-5):200-10.
PMID: 21664759
PMC: 3179838.
DOI: 10.1016/j.diff.2011.05.007.
Nitric oxide synthase 2 gene polymorphisms are associated with prostatic volume in Korean men with benign prostatic hyperplasia.
Yoo K, Kim S, Chung J, Chang S
Asian J Androl. 2010; 12(5):690-6.
PMID: 20562898
PMC: 3739311.
DOI: 10.1038/aja.2010.37.
Comprehensive identification and modified-site mapping of S-nitrosylated targets in prostate epithelial cells.
Lam Y, Yuan Y, Isaac J, Suresh Babu C, Meller J, Ho S
PLoS One. 2010; 5(2):e9075.
PMID: 20140087
PMC: 2816712.
DOI: 10.1371/journal.pone.0009075.
Sildenafil citrate and tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction.
Tuncel A, Nalcacioglu V, Ener K, Aslan Y, Aydin O, Atan A
World J Urol. 2009; 28(1):17-22.
PMID: 19855976
DOI: 10.1007/s00345-009-0484-z.
[Pathophysiology and therapy of benign prostatic hyperplasia].
Sampson N, Madersbacher S, Berger P
Wien Klin Wochenschr. 2008; 120(13-14):390-401.
PMID: 18726663
DOI: 10.1007/s00508-008-0986-5.
The nitric oxide pathway in the human prostate: clinical implications in men with lower urinary tract symptoms.
Kedia G, Uckert S, Jonas U, Kuczyk M, Burchardt M
World J Urol. 2008; 26(6):603-9.
PMID: 18607596
DOI: 10.1007/s00345-008-0303-y.